Company Overview

Longeveron Inc. is a clinical-stage biotechnology company focused on regenerative medicine and cellular therapies. The company develops investigational treatments derived from medicinal signaling cells (MSCs), with an emphasis on aging-related and life-threatening conditions. Longeveron operates primarily within the biotechnology, regenerative medicine, and cell therapy industries, targeting unmet medical needs in areas such as Alzheimer’s disease, pediatric hypoplastic left heart syndrome (HLHS), and acute respiratory distress syndrome (ARDS). The company’s primary value driver is the development and commercialization potential of its proprietary stem cell-based therapeutic platform.

The company was founded in 2014 and is headquartered in Miami, Florida. Longeveron evolved from academic and clinical research led by physicians and scientists specializing in regenerative medicine and cardiovascular disease. Its strategic positioning is tied to its intellectual property portfolio, clinical trial development capabilities, and focus on aging-related disorders where few approved regenerative therapies currently exist. The company has also pursued orphan disease opportunities and FDA regulatory pathways intended to accelerate development timelines for select indications.

Business Operations

Longeveron’s operations are centered on the research, clinical development, manufacturing, and regulatory advancement of its proprietary cell therapy product candidate, Lomecel-B. The company generates no significant commercial product revenue as of publicly available filings and primarily finances operations through equity offerings, public market financing, grants, and research-related funding. Its business activities include conducting clinical trials, managing manufacturing processes for cellular therapies, and advancing intellectual property associated with MSC technologies.

The company’s operational footprint includes clinical collaborations with hospitals, academic institutions, and research centers in the United States. Longeveron maintains internal capabilities related to cell processing and therapy development while also relying on third-party manufacturing, clinical research organizations, and specialized medical partners for portions of its clinical and operational activities. Public disclosures identify the company’s lead therapeutic asset, Lomecel-B, as the core platform supporting multiple clinical programs across cardiovascular, neurological, and inflammatory disease applications.

Strategic Position & Investments

Longeveron’s strategic direction is focused on advancing late-stage clinical development for regenerative medicine therapies addressing diseases associated with aging and severe inflammatory conditions. The company has emphasized regulatory engagement with the U.S. Food and Drug Administration, including orphan drug and fast-track-related pathways where applicable. Its growth strategy is based on expanding clinical evidence for Lomecel-B across multiple indications while strengthening manufacturing consistency and commercialization readiness.

The company has invested significantly in clinical trial programs involving Alzheimer’s disease and pediatric cardiovascular disorders, particularly HLHS. Longeveron’s strategic positioning also reflects broader industry interest in cell-based therapeutics and longevity-related healthcare solutions. Public filings and investor materials indicate that the company continues to evaluate partnerships, grant-supported initiatives, and institutional collaborations to support clinical advancement and operational scalability. Data regarding large-scale acquisitions or extensive subsidiary holdings remains limited based on available public sources.

Geographic Footprint

Longeveron’s primary operations are based in the United States, with headquarters located in Miami, Florida. Its clinical development activities are concentrated largely within U.S.-based healthcare and research institutions, including hospitals and specialty treatment centers participating in clinical studies. The company’s regulatory strategy is also principally aligned with U.S. FDA oversight and domestic clinical development pathways.

While Longeveron does not currently maintain the broad multinational commercial infrastructure seen in larger biotechnology firms, its therapeutic focus addresses global markets associated with aging populations and chronic disease management. The company has indicated interest in expanding the international relevance of its therapies through scientific collaborations and broader regulatory engagement, though current publicly verified operations remain predominantly U.S.-centered.

Leadership & Governance

Longeveron was founded by regenerative medicine researchers and clinicians, including Joshua M. Hare, M.D., who has played a central role in the company’s scientific direction and development strategy. Leadership has consistently emphasized evidence-based clinical advancement, regulatory engagement, and the development of regenerative therapies targeting unmet medical needs associated with aging and severe disease conditions.

Key executives and leadership figures include:

• Wa’el Hashad, M.D. – Chief Executive Officer
• Joshua M. Hare, M.D. – Founder and Chief Science Officer
• Lisa Locklear – Chief Financial Officer
• Pamela R. West – Vice President, Regulatory Affairs
• David Green – General Counsel and Corporate Secretary

The company’s governance framework reflects standard public biotechnology company practices, including oversight by a board of directors and compliance with reporting obligations under SEC filings and Nasdaq listing requirements. Leadership communications have consistently focused on clinical validation, regulatory execution, and long-term development of regenerative medicine platforms.